Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma
- 123 Downloads
Purpose: To evaluate the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics of thalidomide in patients with advanced hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC who were not feasible for definitive local therapy were eligible. Patients were enrolled in a cohort of three to receive thalidomide twice daily for 1 week to determine the MTD. Intra-patient dose escalation was permitted. Pharmacokinetic studies were performed at the first dose level and repeated at the second dose level of each patient. Results: Fifteen patients were accrued at four dose levels with the starting dose range 100–400 mg/day. Two patients at 400 mg/day experienced DLT (grade 3 angioedema and dyspnea, respectively). The MTD of twice-daily schedule was determined as 300 mg/day. The mean steady-state maximal blood concentration and mean steady-state area under the curve had a trend toward positive correlation, but non-linear proportionate, to the daily dose of thalidomide. Pharmacokinetic parameters are comparable for patients of Child-Pugh’s A and B. Apparent mild, transient drug-induced transaminitis was early onset, self-limited, which occurred in 30.7% of patients. Serum hepatitis B or C viral titers was largely not affected. Conclusion: The absorption and elimination of thalidomide are not significantly different in HCC patients with compensated or decompensated hepatic dysfunction.
KeywordsCirrhosis Maximum tolerated dose Angiogenesis inhibitor Hepatitis virus
This work was supported by intramural grant of National Health Research Institutes, no. NHRI-89A1-CAQOVGHWRD.
- 14.Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E (2001) Randomized phase II study of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 7:1888–1893PubMedGoogle Scholar
- 25.Huang JD, Chen RRL, Oie S (1984). Microfit: a Basic program for non-linear regression analysis of pharmacokinetic data using a microcomputer. J Taiwan Pharmaceutical Asso 36:69–81Google Scholar
- 30.Kong HL, Boyer MJ, Lim R, Clarke S, Millward MJ, Wong JE (2001) Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC): a Cancer Therapeutics Research Group (CTRG) study. Proc Am Soc Clin Oncol 20:133bGoogle Scholar
- 33.Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock T, Levitt L (2002) Phase II study of thalidomide in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 21:97bGoogle Scholar
- 34.Lin TM, Chen CJ, Tsai SF, Tsai TH (1988) Hepatoma in Taiwan. J Natl Public Health Assoc (ROC) 8:91–100Google Scholar
- 37.Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M (1991) Benign and malignant nodules in cirrhotic liver: distinction based on blood supply. Radiology 78:493–497Google Scholar
- 38.McBride WG (1968) Thalidomide and congenital abnormalities. Lancet 2:1358Google Scholar
- 47.Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958–965CrossRefPubMedGoogle Scholar
- 49.Schwartz JD, Sung MW, Lehrer D, Goldenberg A, Muggia F, Volm M (2002) Thalidomide for unresectable hepatocellular cancer (HCC) with optional interferon-α upon disease progression. Proc Am Soc Clin Oncol 21:10bGoogle Scholar
- 54.Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92:2364–2373CrossRefPubMedGoogle Scholar
- 58.WHO technical report series (1983) Prevention of Liver Cancer. World Health Organization, GenevaGoogle Scholar